

## Three new partners join forces with MATWIN to develop research and translational innovation in oncology

**Bordeaux France, March 11<sup>th</sup> 2024** - For the French cancer week, **Exact Sciences, Takeda** and **insitro** announce they have joined [MATWIN](#), the French national open-innovation platform dedicated to oncology, a fully owned subsidiary of Unicancer, which is celebrating its 15<sup>th</sup> anniversary this year!

The MATWIN platform seeks to accelerate translational research in oncology and thus facilitate the transfer of innovations to patients relying on an ongoing partnership with fourteen international laboratories keen to detect and support projects with development potential (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, insitro, MSD, Pfizer, Pierre Fabre, Roche, Sanofi and Takeda).

*“Our partnership with MATWIN is fully in line with the open-innovation approach that we are pursuing. This collaboration will increase our visibility on innovative projects that can have an impact on early cancer detection and treatment guidance, to take action earlier - when it matters most”* explains **Christophe Rispal, Managing Director, Exact Sciences France**.

Over the last fifteen years, MATWIN has been offering various actions (expertise, accelerator program, entrepreneurship training, events, etc.) to accelerate the development of innovative projects dedicated to the fight against cancer. Mobilizing an international network of industrial and academic partners committed to shortening innovation transfer times, MATWIN has already supported more than 300 projects and fostered the creation of more than 45 startups.

*“MATWIN was visionary fifteen years ago when launching the first French initiative to bring together research and industry ecosystems around innovation in the fight against cancer! In the context of the ongoing structuring of the Paris Saclay Cancer Cluster, of which Gustave Roussy is one of the five founders, the MATWIN expertise and network will be essential assets!”* indicates **Professor Fabrice Barlesi, Gustave Roussy CEO and MATWIN President**.

*“Science is foundational to everything we do at Takeda. Becoming part of the MATWIN Network will enable us to access the exciting innovation in this international ecosystem to accelerate finding solutions to the challenging problems we all face in the quest for breakthrough cancer therapeutics,”* states **Kathy Seidl, Global Head of the Oncology Drug Discovery Unit, Takeda**.

The [MATWIN International Board](#), unique committee of its kind in Europe, brings together around twenty key decision-makers from World Oncology R&D from MATWIN partners laboratories, along with academic opinion leaders from the largest European cancer research centres. It has met every year in France since 2009, to interview supported projects, guide them on their clinical development plan and label those with the highest translational potential.

*“MATWIN is an initiative like few others, and we are excited to join them in their efforts to advance innovations in oncology. This is a unique opportunity for selected candidates to compare their work with internationally renowned experts in oncology R&D whose feedback will boost the projects’ development. insitro’s mission is to bring better drugs faster to the patients who can benefit most, and partnerships such as this, are essential to achieving that goal. »* reports **Philip Tagari, Chief Scientific Officer insitro**.

## **ABOUT MATWIN**

*MATWIN, a subsidiary of Unicancer, is the only French open-innovation platform specifically dedicated to oncology. For fifteen years, the platform has offered various actions (accelerator program, entrepreneurship training, events, etc.) aimed at accelerating the development potential of French or European projects, offering innovative products or solutions applied to the field of oncology. The platform is based on a historic partnership with fourteen international laboratories (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, insitro, MSD, Pfizer, Pierre Fabre, Roche, Sanofi and Takeda) committed to developing partnerships in the field.*

*Each year MATWIN organizes the European Partnering Convention dedicated to oncology [MEET2WIN](#), which brings together more than 300 European players in the cancer innovation chain and thus promotes collaborations between ecosystems (companies, entrepreneurs, researchers, clinicians, investors, structures support, patient associations, etc.). 9th<sup>edition</sup> on May 16 & 17 in Bordeaux: [www.meet2win.fr](http://www.meet2win.fr)*

*Since 2021, MATWIN has also coordinated the [OncoSTART consortium](#) dedicated to entrepreneurship in oncology, which brings together 14 expert organizations in cancer research and innovation.*

*More information on: [www.matwin.fr](http://www.matwin.fr)*

## **ABOUT EXACT SCIENCES**

*A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and healthcare professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard®(available only in the United States) and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.*

*More information: [www.exactsciences.com](http://www.exactsciences.com)*

## **ABOUT TAKEDA**

*Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.*

*More information: [www.takeda.com](http://www.takeda.com)*

## **ABOUT INSITRO**

*insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro's approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. These data are used to develop ML models that expand insitro's data tensor via imputation, uncover underlying biologic state, and elucidate high-impact genetic modulators of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics, and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology, and metabolism. Since launching in 2018, insitro has raised over \$700 million from top tech, biotech, and crossover investors, and from collaborations with pharmaceutical partners.*

*More information: [www.insitro.com](http://www.insitro.com)*

---

### **Press contacts:**

MATWIN - Lucia Robert - [lucia.robert@matwin.fr](mailto:lucia.robert@matwin.fr)

EXACT SCIENCES – Christophe Rispal - [crispal@exactsciences.com](mailto:crispal@exactsciences.com)

TAKEDA – Laurence Simon - [laurence.simon@madisphileo.com](mailto:laurence.simon@madisphileo.com) & Camille Le Fur – [camille.lefur@takeda.com](mailto:camille.lefur@takeda.com)

INSITRO – Dan Budwick – [dan@1abmedia.com](mailto:dan@1abmedia.com)